<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05098665</url>
  </required_header>
  <id_info>
    <org_study_id>C21026</org_study_id>
    <nct_id>NCT05098665</nct_id>
  </id_info>
  <brief_title>PATHWAY-RCT: Preventing Admission To Hospital in wtATTR Cardiomyopathy</brief_title>
  <acronym>PATHWAY-RCT</acronym>
  <official_title>PATHWAY-RCT: Preventing Admission To Hospital in wtATTR Cardiomyopathy Using Remote Cardiac Telemonitoring</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Jorg Taubel</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Richmond Pharmacology Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Amyloidosis Centre</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Richmond Pharmacology Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cardiac amyloidosis is a condition where the heart muscle, amongst other tissues, is&#xD;
      infiltrated by the abnormal build-up of proteins called amyloid. This stiffens and thickens&#xD;
      the heart muscle over time which makes it less efficient and puts further stress and strain&#xD;
      on the other chambers of the heart, leading to heart failure. The commonest form, that&#xD;
      affects predominantly the elderly, is called 'wild-type' ATTR amyloid (TTR is the protein&#xD;
      that accumulates). In this condition a patient has a 60% chance of admission to hospital each&#xD;
      year after diagnosis. There is no current treatment for ATTR amyloid other than using water&#xD;
      tablets to reduce excess fluid and prevent more serious fluid build up in lungs and other&#xD;
      tissues. Increasing body weight is the most reliable clinical sign of this fluid build up.&#xD;
&#xD;
      Tele-monitoring is the practice of monitoring patients from a distance and has been shown to&#xD;
      reduce heart failure admissions and death in patients with heart failure from any cause. Due&#xD;
      to reduced access to primary and secondary care during COVID-19 the investigators instigated&#xD;
      tele-monitoring of heart failure in ATTR amyloid patients. This appeared to be an effective&#xD;
      intervention in the pilot study. The investigators propose to monitor the weight of patients&#xD;
      with cardiac amyloidosis at home and intervene where a build up of fluid is observed by&#xD;
      telephone discussion with a doctor. The investigators propose to evidence this in a&#xD;
      prospective clinical trial. The investigators will evaluate the effect fairly by comparing&#xD;
      tele-monitoring with usual care.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2022</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Heart-failure related hospitalisations</measure>
    <time_frame>Study duration (3 years)</time_frame>
    <description>Hospitalisation which can be attributed to heart failure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>Study duration (3 years)</time_frame>
    <description>Death by any cause, as an annual event rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause hospitalisation</measure>
    <time_frame>Study duration (3 years)</time_frame>
    <description>Hospitalisation for any reason</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Cardiac Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Arm A - RCT telemonitoring</arm_group_label>
    <description>160 ATTR-CM patients assigned to receive telemonitoring intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - RCT usual care</arm_group_label>
    <description>Control group of 160 ATTR-CM patients assigned to receive usual care</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Telemonitoring</intervention_name>
    <description>A remote weight monitoring device (BodyTrace) will be delivered to the volunteers home and advice given where to place it ( on a hard surface) and how often to use it (daily, after waking and urination, but before breakfast).&#xD;
Arm A will receive the intervention.</description>
    <arm_group_label>Arm A - RCT telemonitoring</arm_group_label>
    <other_name>BodyTrace</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study population for Arm A and B is community wtATTR patients attending outpatients at&#xD;
        the National Amyloidosis Centre&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Adults aged â‰¥18 at the date of signing informed consent which is defined as the&#xD;
             beginning of the Screening Period.&#xD;
&#xD;
          2. An established diagnosis of ATTR cardiomyopathy as defined by protocol.&#xD;
&#xD;
          3. Ability to provide written, personally signed and dated informed consent to&#xD;
             participate in the study, in accordance with the ICH Good Clinical Practice (GCP)&#xD;
             Guideline E6 (R2) (2016) and applicable regulations, before completing any&#xD;
             study-related procedures.&#xD;
&#xD;
          4. An understanding, ability, and willingness to fully comply with study procedures and&#xD;
             restrictions.&#xD;
&#xD;
          5. Currently a patient at a study site (NAC).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. An inability to have or use BodyTrace device scales at usual residence (for example no&#xD;
             mobile network cellular signal)&#xD;
&#xD;
          2. On dialysis or end-stage renal failure (eGFR &lt;25mL/min)&#xD;
&#xD;
          3. Serum albumin &lt;20g/dL or other non-hypervolaemia cause of tissue oedema (e.g.&#xD;
             protein-losing enteropathy, nephrotic syndrome)&#xD;
&#xD;
          4. Use of greater than 2 oral diuretics (e.g. on maximum oral diuretic therapy)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamer Rezk, MBBS MRCP PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Amyloidosis Centre, Royal Free Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dominic Pimenta, MBBS MRCP BSc (Hons)</last_name>
    <phone>02070425800</phone>
    <email>grants@richmondresearchinstitute.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Keith Berelowitz</last_name>
    <phone>02070425800</phone>
    <email>k.berelowitz@richmondpharmacology.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Richmond Research Institute</name>
      <address>
        <city>London</city>
        <zip>SW17 0RE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Dominic Pimenta, MBBS MRCP BSc (Hons)</last_name>
      <email>grants@richmondresearchinstitute.org</email>
    </contact>
    <investigator>
      <last_name>Jorg Taubel, MD FFPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 15, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Richmond Research Institute</investigator_affiliation>
    <investigator_full_name>Dr Jorg Taubel</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Sharing of personal data with other organisations is not planned</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

